Hong Li
Clinical Genetics (M.D.) · Decatur, GANPI 1811160609
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $95,640 of the $97,925 with a category attached, or 97.7%. Ultragenyx Pharmaceutical Inc. accounts for 68.5% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $91,357, more than ten times the $368 reported in 2019.
Across 30 payments — averaging $3264.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ultragenyx Pharmaceutical Inc.$67K
- AbbVie$17K
- Biomarin Pharmaceutical Inc.$6K
- Travere Therapeutics, Inc.$6K
- PTC Therapeutics, Inc.$1K
- Amgen$243
Across 51 payments — averaging $4857.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$122K
- Biomarin Pharmaceutical Inc.$67K
- Ultragenyx Pharmaceutical Inc.$32K
- Modernatx, Inc.$19K
- AstraZeneca$8K
What the payments were for
- Consulting fees$95,64098%
- Speaking & faculty fees$6251%
- Travel & lodging$1,3841%
- Food & beverage$2760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 6 | $67,040 |
| AbbVie | 7 | $17,400 |
| Biomarin Pharmaceutical Inc. | 12 | $6,042 |
| Travere Therapeutics, Inc. | 3 | $6,000 |
| PTC Therapeutics, Inc. | 1 | $1,200 |
| Amgen | 1 | $243 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical genetics (m.d.) providers in Georgiato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FabrazymeAgalsidase Beta | 13 | $465,476 |
| PalynziqPegvaliase-Pqpz | 16 | $199,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biomarin Pharmaceutical Inc.Palynziq | $6,042 | $199,80516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical genetics (m.d.) providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other clinical genetics (m.d.) in Decatur
- William WilcoxDecatur$71K
- Michael GambelloDecatur$5K
- Suma ShankarDecatur$4K
- Jaime Vengoechea BarriosAtlanta$26K
- Rossana Sanchez RussoAtlanta$375
- Faizal AsumdaAugusta$307
- Kristen MurpheyAtlanta$163
- David FlanneryAugusta$48
- Cynthia MooreGainesville$6
- Juanita Neira FresnedaAtlanta$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.